Dr. Kulkarni completed his medical school and residency in urology at the University of Toronto. During his residency, he entered the Surgeon Scientist Training Program and completed his PhD in clinical epidemiology through the Institute of Health Policy, Management and Evaluation. He then completed a fellowship in urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York City.

Dr. Girish Kulkarni joined the uro-oncology faculty in 2011 and is a urologic surgeon in the Department of Surgical Oncology at the Princess Margaret Cancer Centre, University Health Network. He is also a surgeon-scientist who is affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto. At the University of Toronto, he is an associate professor in the Department of Surgery, as well as at the Institute of Health Policy, Management and Education. He also holds a senior adjunct scientist position at the Institute for Clinical Evaluative Sciences. Dr. Kulkarni’s main clinical interests are in bladder and prostate cancer. He is also highly involved in the management of “orphan” genitourinary malignancies including urothelial carcinoma of the upper tract and penile carcinoma.

Dr. Kulkarni’s primary research interests revolve around the epidemiology of genitourinary malignancies, particularly bladder cancer. His investigations are dedicated towards the understanding of population-level quality of care of urologic malignancies, quality of life and the health economics associated with urologic malignancies. He is also actively involved in clinical trials and is the site principal investigator for numerous non-muscle invasive and muscle invasive bladder cancer trials at the Princess Margaret Cancer Centre. He is an active member of Bladder Cancer Canada and serves on its medical advisory board.

Examples of his innovative work in bladder cancer include the development and validation of the Bladder Utility Symptom Scale (BUSS), which is a health related quality of life tool that helps clinicians rapidly measure quality of life in all bladder cancer patients and which will help policy makers determine the cost-effectiveness of bladder cancer treatments. This instrument is being adopted into clinical practice worldwide. He has also promoted the use of bladder-sparing trimodal therapy for patients with muscle invasive bladder cancer and is an established member of the University Health Network’s Multidisciplinary Bladder Cancer Clinic. His work in bladder cancer has been presented at multiple national and international meetings and is currently funded by the Canadian Institutes for Health Research.

If you are looking for local services or  treatment  from your Local Urologist in the office or hospital from a Local Urologist, contact a provider such as ( Dr. Girish Kulkarni ) to inquire if they are accepting patients or you need a referral.   Phone number to book an appointment 14169799000

The speaker in the video may have no association with ( Dr. Girish Kulkarni, Local Urologist Toronto, ON ). 
( Dr. Girish Kulkarni, Local Urologist Toronto, ON ), may talk about some of the conditions and some of the treatment options shown on the videos. Always talk with your Local Urologist about the information you learnt from the videos in regards to treatments and procedures the Local Urologist could  perform and if they would be appropriate for you. Remember good information is the corner stone to understanding your condition or disease. Please contact ( Dr. Girish Kulkarni, Local Urologist Toronto, ON ) to enquire if this health care provider is accepting new patients. Prostate Cancer NOW is part of the Now Health Network and its focus is on muscular and skeletal  conditions

Urology Information: 

Depending on the case, prostate cancer may be safely followed with active surveillance or watchful waiting rather than surgery, chemotherapy or radiation. Ask your local urologist for more information on Contino®, an alternative to diapers or surgery. Patients may be referred to a urologist if their physician suspects they may need treatment for a condition relating to bladder, urethra, ureters, kidneys, and adrenal glands.

Urethral inserts like Contino® are temporarily inserted into the urethra (the tube which carries urine to the outside of the body) to prevent or reduce bladder leakage. Depending on the case, prostate cancer may be safely followed with active surveillance or watchful waiting rather than surgery, chemotherapy or radiation. Prostate cancer is the most common cancer in Canadian men. It is most common in older men

Colorectal ; Other Cancers: Dietary fibre and antioxidant intake are two of the biggest considerations
when it comes to reducing the risk of preventable cancers, such as colorectal cancer. Beets and beet
greens are among the most abundant sources of both these important nutrients.

Your body will digest and absorb short-chain carbohydrates (also called rapid-acting carbohydrates) more quickly, which can actually cause a spike in the blood sugar. Some examples would be juice, white bread and sugar. Longer-chain carbohydrates take the body longer to digest and absorb, causing less of an effect on the blood sugar. Examples are legumes, oats, barley and berries. These carbohydrates can play a very important role in diabetes management. 

Surgery for prostate cancer is called a radical prostatectomy and involves the removal of the prostate gland with or without some lymph nodes in the pelvis. This can be performed with key-hole surgery called laparoscopy (usually done with a robot to help the surgeon) or through a small incision in the lower part of the abdomen called open surgery.

Once prostate cancer is diagnosed, one of the first things doctors do is determine how aggressive cancers are (also known as tumor grade) and how much of the prostate is involved and if the cancer has spread outside of the gland to nearby tissues or other parts of the body (otherwise known as tumor stage). This information is important to help determine the treatment options for men newly diagnosed with prostate cancer. What is tumor Grade?:

When a tumor is discovered on prostate biopsy, the aggressiveness of the cancer can be classified into a category called tumor grade. In general, the higher the grade, the more aggressive cancers are. In prostate cancer, the grade is most commonly described as a Gleason Score. The Gleason Score of a prostate cancer is between 2-10. Scores 6 or less are considered mildly aggressive, 7 is considered intermediate aggressive, and scores 8-10 are considered very aggressive. In summary, the higher the Gleason Score, the more aggressive the cancer is, and the greater the risk of cancer spreading outside of the prostate gland. What is tumor Stage?: Often seeing a local urologist in Toronto can help.